Insmed reported $-112714000 in Net Income for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Net Income Change
Acelrx Pharmaceuticals ACRX:US $ -8.38M 1.48M
Alexion Pharmaceuticals ALXN:US $ 636M 100.2M
Arena Pharmaceuticals ARNA:US $ -196.31M 50.22M
Biomarin Pharmaceutical BMRN:US $ -36.49M 49.44M
Cytokinetics CYTK:US $ -76.09M 14.53M
Flexion Therapeutics FLXN:US $ -30312000 8.1M
Gilead Sciences GILD:US $ 2592M 1070M
Insmed INSM:US $ -112714000 4.61M
Mirati Therapeutics MRTX:US $ -80.05M 86.38M
Novartis NVS:US $ 2758M 138M
Regeneron Pharmaceuticals REGN:US $ 1632.2M 1466.7M
Sarepta Therapeutics SRPT:US $ -48.14M 33.26M
Seattle Genetics SGEN:US $ -293.85M 209.27M
Ultragenyx Pharmaceutical RARE:US $ -73M 49.43M
Vertex Pharmaceuticals VRTX:US $ 851.93M 785M